Melanoma in a Colombian population: a survival study

References

• Simões MCF, Sousa JJS, Pais AACC. Skin cancer and new treatment perspectives: a review. Cancer Lett. 2015;357(1):8–42. doi:10.1016/j.canlet.2014.11.001
   PubMed Web of Science ®Google Scholar
• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. 2018;392(10151):971–984. doi:10.1016/S0140-6736(18)31559-9
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am. 2020;100(1):1–12. doi:10.1016/j.suc.2019.09.005
   PubMed Web of Science ®Google Scholar
• Pozzobon FC, Acosta ÁE, Castillo JS. Cáncer de piel en Colombia: cifras del Instituto Nacional de Cancerología [Skin Cancer in Colombia: Statistics from the National Cancer Institute]. Rev la Asoc Colomb Dermatología y Cirugía Dermatológica. 2018;26(1):12–17. Spanish. doi:10.29176/2590843X.25
   Google Scholar
• Boussios S, Rassy E, Samartzis E, et al. Melanoma of unknown primary: new perspectives for an old story. Crit Rev Oncol Hematol. 2021;158. doi:10.1016/j.critrevonc.2020.103208
   Web of Science ®Google Scholar
• Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495. doi:10.1001/jamadermatol.2022.0160
   PubMed Web of Science ®Google Scholar
• Pozzobon FC, Acosta AE. Epidemiological profile of primary cutaneous melanoma over a 15-year period at a private skin cancer center in Colombia. Rev Salud Publica (Bogota). 2018;20(2):226–231. doi:10.15446/rsap.V20n2.65616
   PubMedGoogle Scholar
• Li WQ, Qureshi AA, Ma J, et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol. 2013;31(35):4394–4399. doi:10.1200/JCO.2013.51.1915
   PubMed Web of Science ®Google Scholar
• Sitenga JL, Aird G, Ahmed A, et al. Socioeconomic status and survival for patients with melanoma in the United States: an NCDB analysis. Int. J. Dermatol. 2018;57(10):1149–1156. doi:10.1111/ijd.14026
   PubMed Web of Science ®Google Scholar
• Vernali S, Waxweiler WT, Dillon PM, et al. Association of incident amelanotic melanoma with phenotypic characteristics, MC1R status, and prior amelanotic melanoma. JAMA Dermatology. 2017;153(10):1026–1031. doi:10.1001/jamadermatol.2017.2444
   PubMed Web of Science ®Google Scholar
• Vourc'H-Jourdain M, Martin L, Barbarot S, et al. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol. 2013;68(3):493–498; e1–e14. doi:10.1016/j.jaad.2012.09.039
   PubMed Web of Science ®Google Scholar
• Reddy KK, Farber MJ, Bhawan J, et al. Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatology. 2013;149(8):928–934. doi:10.1001/jamadermatol.2013.4440
   PubMed Web of Science ®Google Scholar
• Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012;87(10):991–1003. doi:10.1016/j.mayocp.2012.04.018
   PubMed Web of Science ®Google Scholar
• Revythis A, Shah S, Kutka M, et al. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics. 2021;11(8):1341. doi:10.3390/diagnostics11081341
   Web of Science ®Google Scholar
• Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Prim. 2015;1:15003. doi:10.1038/nrdp.2015.3
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362. doi:10.1038/s41392-021-00670-9
   PubMed Web of Science ®Google Scholar
• Slominski RM, Sarna T, Płonka PM, et al. Melanoma, melanin, and melanogenesis: the Yin and Yang relationship. Front Oncol. 2022;12:842496. doi:10.3389/fonc.2022.842496
   PubMed Web of Science ®Google Scholar
• Janka EA, Várvölgyi T, Sipos Z, et al. Predictive Performance of Serum S100B Versus LDH in melanoma patients: a systematic review and meta-analysis. Front Oncol. 2021;11. doi:10.3389/fonc.2021.77216
   Web of Science ®Google Scholar
• Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021;19(4):364–376. doi:10.6004/jnccn.2021.0018
   PubMed Web of Science ®Google Scholar
• Green AC, Baade P, Coory M, et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30(13):1462–1467. doi:10.1200/JCO.2011.38.8561
   PubMed Web of Science ®Google Scholar
• Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199–2205. doi:10.1200/JCO.2010.31.5812
   PubMed Web of Science ®Google Scholar
• Tseng WH, Martinez SR. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res. 2011;167(2):192–198. doi:10.1016/j.jss.2010.10.008
   PubMed Web of Science ®Google Scholar
• Johansson M, Brodersen J, Gøtzsche PC, et al. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database Syst Rev. 2019;6(6):CD012352. doi:10.1002/14651858.CD012352.pub2
   PubMedGoogle Scholar
• Yuan TA, Lu Y, Edwards K, et al. Race-, age-, and anatomic site-specific gender differences in cutaneous melanoma suggest differential mechanisms of early- and late-onset melanoma. Int J Environ Res Public Health. 2019;16(6):908. doi:10.3390/ijerph16060908
   PubMed Web of Science ®Google Scholar
• Chevalier V, Barbe C, Le Clainche A, et al. Comparison of anatomical locations of cutaneous melanoma in men and women: a population-based study in France. Br. J. Dermatol. 2014;171(3):595–601. doi:10.1111/bjd.13052
   PubMed Web of Science ®Google Scholar
• Wee E, Wolfe R, Mclean C, et al. The anatomic distribution of cutaneous melanoma: a detailed study of 5141 lesions. Australas J Dermatol. 2020;61(2):125–133. doi:10.1111/ajd.13223
   PubMed Web of Science ®Google Scholar
• Iribarren O, Sepúlveda M, Hidalgo J, et al. Epidemiological study of malignant melanoma in IV Region of Chile. Cuad cir. 2005;33–38.
   Google Scholar
• Pérez ME, Bley C, Cárdenas C, et al. Epidemiology of melanoma in the O'Higgins region during the years 2012 and 2015. Rev Chil Dermatol. 2017;33(4):43–48.
   Google Scholar
• Ortiz PAU, Villanueva JAN, Mejia CCC, et al. Characteristic features of cutaneous melanoma in two institutions of Bogotá, Colombia: analysis, 2012–2016. Rev Colomb Cancerol. 2021;25(4):188–195. doi:10.35509/01239015.692
   Google Scholar
• Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022;170:256–284. doi:10.1016/j.ejca.2022.04.018
   PubMed Web of Science ®Google Scholar
• Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2(2):CD011123. doi:10.1002/14651858.CD011123.pub2
   PubMedGoogle Scholar
• Wheatley K, Wilson JS, Gaunt P, et al. Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation. Cancer Treat Rev. 2016;42:73–81. doi:10.1016/j.ctrv.2015.10.013
   PubMed Web of Science ®Google Scholar
• Goepfert RP, Myers JN, Gershenwald JE. Updates in the evidence-based management of cutaneous melanoma. Head Neck. 2020;42(11):3396–3404. doi:10.1002/hed.26398
   PubMed Web of Science ®Google Scholar
• Curti B, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384(23):73–74. doi:10.1056/NEJMra2034861
   Web of Science ®Google Scholar
• Behbahani S, Malerba S, Samie FH. Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004–2016. Br J Dermatol. 2020;183(5):952–954. doi:10.1111/bjd.19211
   PubMed Web of Science ®Google Scholar
• Mejbel HA, Torres-Cabala CA, Milton DR, et al. Prognostic significance of acral lentiginous histologic type in T1 melanoma. Mod Pathol. 2021;34(3):572–583. doi:10.1038/s41379-020-0641-x
   PubMed Web of Science ®Google Scholar
• Svedman FC, Pillas D, Taylor A, et al. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol. 2016;8:109–122. doi:10.2147/CLEP.S99021
   PubMed Web of Science ®Google Scholar
• Rodríguez-Betancourt JD, Arias-Ortiz N. Cutaneous melanoma incidence, mortality, and survival in Manizales, Colombia: a population-based study. J Int Med Res. 2022;50(6):3000605221106706. doi:10.1177/03000605221106706
   Web of Science ®Google Scholar
• Vazquez VDL, Silva TB, Vieira MDA, et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes. 2015;8(1):4. doi:10.1186/s13104-015-0972-8
   PubMedGoogle Scholar
• Reyes E, Uribe C, de Vries E. Population-based incidence and melanoma-specific survival of cutaneous malignant melanoma in a Colombian population 2000–2009. Int J Dermatol. 2018;57(1):21–27. doi:10.1111/ijd.13839
   PubMed Web of Science ®Google Scholar
• Lino-Silva LS, Domínguez-Rodríguez JA, Aguilar-Romero JM, et al. Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype. Ann Surg Oncol. 2016;23(13):4189–4194. doi:10.1245/s10434-016-5394-x
   PubMed Web of Science ®Google Scholar